Moderna races to create norovirus vaccines

As norovirus cases increase across the U.S., Moderna is conducting a phase 3 trial with 25,000 participants to test its experimental vaccine, CNBC reported.

The vaccine manufacturer is recruiting for the study across the U.S., Canada, U.K., Japan, the equatorial region, Australia and countries in South America. About 20,000 trial subjects will be ages 60 and up, and the other 5,000 will be between 18 and 59 years old.